Cost-effectiveness of chemotherapy in non-small-cell lung cancer - In reply

被引：0
|
作者：
Leighl, NB [1 ]
Shepherd, FA
Goodwin, PJ
机构：
[1] Univ Toronto, Princess Margaret Hosp, Univ Hlth Network, Toronto, ON, Canada
[2] Univ Toronto, Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2002年 / 20卷 / 17期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
下载
收藏
页码：3751 / 3752
页数：2
相关论文
共 50 条
  • [1] Cost-effectiveness of chemotherapy in non-small-cell lung cancer
    Saglam, S
    Yetis, B
    Ozyilkan, O
    Akçali, Z
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (17) : 3750 - 3751
  • [2] Cost-effectiveness of atezolizumab plus chemotherapy for advanced non-small-cell lung cancer
    Shen Lin
    Shaohong Luo
    Lixian Zhong
    Shubin Lai
    Dayong Zeng
    Xin Rao
    Pinfang Huang
    Xiuhua Weng
    International Journal of Clinical Pharmacy, 2020, 42 : 1175 - 1183
  • [3] Cost-effectiveness of atezolizumab plus chemotherapy for advanced non-small-cell lung cancer
    Lin, Shen
    Luo, Shaohong
    Zhong, Lixian
    Lai, Shubin
    Zeng, Dayong
    Rao, Xin
    Huang, Pinfang
    Weng, Xiuhua
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2020, 42 (04) : 1175 - 1183
  • [4] Cost-effectiveness of camrelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer
    Liang, Xueyan
    Chen, Xiaoyu
    Li, Huijuan
    Li, Yan
    IMMUNOTHERAPY, 2023, 15 (14) : 1133 - 1142
  • [5] Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer in China
    Zhang, Xin
    Zhang, Huixian
    Feng, Lei
    Liu, Qiao
    RISK MANAGEMENT AND HEALTHCARE POLICY, 2023, 16 : 1849 - 1857
  • [6] Cost-effectiveness associated with the diagnosis and staging of non-small-cell lung cancer
    Osada H.
    Kojima K.
    Tsukada H.
    Nakajima Y.
    Imamura K.
    Matsumoto J.
    The Japanese Journal of Thoracic and Cardiovascular Surgery, 2001, 49 (1): : 1 - 10
  • [7] Sugemalimab plus chemotherapy vs. chemotherapy for metastatic non-small-cell lung cancer: A cost-effectiveness analysis
    Liang, Xueyan
    Chen, Xiaoyu
    Li, Huijuan
    Liu, Xiaoxia
    Li, Yan
    FRONTIERS IN PUBLIC HEALTH, 2023, 11
  • [8] Toripalimab plus chemotherapy vs. chemotherapy in patients with advanced non-small-cell lung cancer: A cost-effectiveness analysis
    Huo, Gengwei
    Liu, Wenjie
    Kang, Shuo
    Chen, Peng
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [9] Cost-Effectiveness of Pembrolizumab for the treatment of Non-Small-Cell lung cancer: A systematic review
    Zhang, Chuan
    Zhang, Jiaxu
    Tan, Jing
    Tian, Panwen
    Li, Weimin
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [10] Cost-Effectiveness of Multiplexed Predictive Biomarker Screening in Non-Small-Cell Lung Cancer
    Romanus, Dorothy
    Cardarella, Stephanie
    Cutler, David
    Landrum, Mary Beth
    Lindeman, Neal I.
    Gazelle, G. Scott
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (04) : 586 - 594
12345